Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent developments in Barrett's esophagus.

H S Garewal1

  • 1Section of Hematology/Oncology, Southern Arizona Veteran's Administration Health Care System, 3601 South Sixth Avenue, Tucson, AZ 85723, USA. Hgarewal@azcc.arizona.edu

Current Oncology Reports
|December 21, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discrepancy in the assessment of tumor response in patients with pancreatic cancer: WHO versus RECIST criteria.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology·2008
Same author

Correlation of gastroesophageal reflux disease symptoms characteristics with long-segment Barrett's esophagus.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus·2006
Same author

Non-erosive reflux disease (NERD)--acid reflux and symptom patterns.

Alimentary pharmacology & therapeutics·2003
Same author

Short segment Barrett's esophagus: relationship of age with extent of intestinal metaplasia.

The American journal of gastroenterology·2001
Same author

A collaborative end-of-life care curriculum.

The American journal of hospice & palliative care·2001
Same author

Preferential repair by squamous epithelium of thermal induced injury to the proximal stomach in patients undergoing ablation of Barrett's esophagus.

Gastrointestinal endoscopy·2001

Barrett's esophagus, a precancerous condition, involves esophageal lining changes. Identifying high-risk patients using biomarkers like p53 is crucial for managing esophageal adenocarcinoma risk.

Area of Science:

  • Gastroenterology
  • Oncology
  • Molecular Biology

Background:

  • Barrett's esophagus is a precancerous condition characterized by esophageal epithelium metaplasia.
  • Specialized columnar epithelium (intestinal metaplasia) is linked to increased esophageal adenocarcinoma risk.
  • Esophageal adenocarcinoma incidence is rising, with gastroesophageal reflux disease and bile-acid reflux implicated.

Purpose of the Study:

  • To review the current understanding of Barrett's esophagus, including its association with esophageal adenocarcinoma.
  • To discuss the role of short-segment Barrett's esophagus and the need for risk stratification.
  • To highlight the importance of biomarker development and potential therapeutic strategies.

Main Methods:

  • Literature review of Barrett's esophagus, esophageal adenocarcinoma, and related risk factors.

Related Experiment Videos

  • Analysis of current diagnostic and surveillance practices.
  • Exploration of emerging biomarkers and therapeutic interventions.

    • Main Results:

    • Barrett's esophagus, particularly specialized columnar epithelium, is a significant risk factor for esophageal adenocarcinoma.
    • Short-segment Barrett's esophagus is under investigation for its role in gastroesophageal junction cancers.
    • p53 is a promising biomarker for identifying high-risk individuals, and redox mechanisms may be involved.
    • Therapeutic strategies for reversing Barrett's esophagus are emerging but require further validation regarding cancer risk reduction.

    Conclusions:

    • Accurate risk stratification is essential for managing Barrett's esophagus due to its increasing prevalence and association with cancer.
    • Biomarker development, such as p53, is critical for personalized surveillance and management.
    • Further research is needed to validate reversal therapies and understand the underlying mechanisms of Barrett's esophagus progression.